Research Topics
Species | Pierre G CoulieSummaryCountry: Belgium Publications
| Collaborators
|
Detail Information
Publications
Human tumor-specific T lymphocytes: does function matter more than number?Pierre G Coulie
Institute of Cellular Pathology, Universite Catholique de Louvain, Avenue Hippocrate 74, UCL 7459, B 1200 Brussels, Belgium
Curr Opin Immunol 17:320-5. 2005..Understanding how an efficient vaccine interferes with this coexistence is one of the current challenges of cancer immunotherapy...
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3P G Coulie
Cellular Genetics Unit, Institute of Cellular Pathology, Cliniques Universitaires Saint Luc, Universite de Louvain, Brussels B1200, Belgium
Proc Natl Acad Sci U S A 98:10290-5. 2001..Even though they provide no information about the effector mechanisms responsible for the observed reduction in tumor mass in this patient, they would suggest that low-level CTL responses can initiate tumor rejection...- T-cell responses of vaccinated cancer patientsPierre G Coulie
Cellular Genetics Unit, Christian de Duve Institute of Cellular Pathology, Universite de Louvain, Avenue Hippocrate 74, UCL 7459, B 1200 Brussels, Belgium
Curr Opin Immunol 15:131-7. 2003..However, a correlation between these T-cell responses and the tumor regressions has not yet been established. It appears that some patients display tumor regression with an unexpectedly low frequency of anti-vaccine T cells... - Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virusVaios Karanikas
Cellular Genetics Unit, Institute of Cellular Pathology, , Brussels, Belgium
J Immunol 171:4898-904. 2003..Taken together, our analysis of anti-MAGE-3.A1 T cell responses following peptide or ALVAC vaccination shows a degree of correlation between CTL response and tumor regression, but firm conclusions will require larger numbers... - High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigensCatherine Germeau
Cellular Genetics Unit, , B-1200 Brussels, Belgium
J Exp Med 201:241-8. 2005..Lurquin, C., B. Lethe, V. Corbiere, I. Theate, N. van Baren, P.G. Coulie, and T. Boon. 2004. J. Exp. Med. 201:249-257)... - Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 moleculesTomoko So
Christian de Duve Institute of Cellular Pathology, Universite Catholique de Louvain, Avenue Hippocrate 74, UCL 7459, 1200 Brussels, Belgium
Cancer Immunol Immunother 56:259-69. 2007..A24 CTL clones. These results suggest that peptide MAGE-A3(195-203) is poorly processed and is not an appropriate target for cancer immunotherapy... - Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigenPierre G Coulie
Cellular Genetics Unit, Institute of Cellular Pathology, , Brussels, Belgium
Immunol Rev 188:33-42. 2002..In 4/9 regressor patients and in 1/14 progressors we found a low level, usually monoclonal cytolytic T lymphocyte response against the MAGE-3 peptide... - Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigenChristophe Lurquin
Cellular Genetics Unit, , B-1200 Brussels, Belgium
J Exp Med 201:249-57. 2005..Naive T cells appear to be stimulated in the course of this process as new antitumor clonotypes arise after vaccination... 
Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalitiesThierry Connerotte
de Duve Institute, Universite Catholique de Louvain, Department of Physiology and Immunology, Medical School of Vrije Universiteit Brussel, Brussels, Belgium
Cancer Res 68:3931-40. 2008....- Comparison of stable human Treg and Th clones by transcriptional profilingJulie Stockis
de Duve Institute, Universite Catholique de Louvain, Brussels, Belgium
Eur J Immunol 39:869-82. 2009..In conclusion, the hallmark of our panel of activated human Treg clones is to produce bioactive TGF-beta which has autocrine actions on Tregs and can have paracrine actions on other T cells... - Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2Wenbin Ma
Ludwig Institute for Cancer Research, Brussels Branch, Avenue Hippocrate 74, UCL 7459, B 1200 Brussels, Belgium
Int J Cancer 109:698-702. 2004..The CTL clones recognizing these 2 peptides also recognized allogeneic tumor cell lines expressing MAGE-C2 and HLA-A2. These 2 new peptides are the first known MAGE-C antigens and represent promising targets for cancer immunotherapy... - Human T cell responses against melanomaThierry Boon
Ludwig Institute for Cancer Research, Brussels Branch, and Cellular Genetics Unit, Universite de Louvain, Brussels, Belgium
Annu Rev Immunol 24:175-208. 2006..In patients who do respond to the vaccine, the antivaccine T cells probably succeed in reversing focally this immunosuppression and trigger a broad activation of other antitumor T cells, which proceed to destroy the tumor... - Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1Takeshi Hanagiri
Christian de Duve Institute of Cellular Pathology, University of Louvain, Avenue Hippocrate 74, UCL 7459, 1200 Brussels, Belgium
Cancer Immunol Immunother 55:178-84. 2006..A1 CTL responses in melanoma patients with a tumor expressing gene MAGE-A3, we measured the blood frequency of anti-MAGE-3.A1 T cells in 45 patients, and found only two clear responses... - Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human TregJulie Stockis
de Duve Institute, Universite Catholique de Louvain, Brussels, Belgium
Eur J Immunol 39:3315-22. 2009.... - Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samplesSophie Lucas
de Duve Institute, Universite Catholique de Louvain, Brussels, Belgium
Int J Cancer 130:1960-6. 2012..Our results imply that analyzing Treg frequencies by quantification of demethylated FOXP3i1 will require that tumor-infiltrating T cells be separated from melanoma cells... - Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?Arcadi Cipponi
de Duve Institute, Universite Catholique de Louvain, Avenue Hippocrate 74, UCL 7459, 1200 Brussels, Belgium
Cancer Immunol Immunother 60:1153-60. 2011..In this context, we review results pertaining to TILs in human melanomas, their prognostic value, and some possible reasons why their presence could help in selecting melanoma patients for vaccination against tumor-specific antigens... - Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastasesArcadi Cipponi
de Duve Institute, Universite Catholique de Louvain, Bruxelles, Belgium
Cancer Res 72:3997-4007. 2012.... - A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytesFrancesca Schiavetti
Cellular Genetics Unit, Christian de Duve Institute of Cellular Pathology, , B-1200 Brussels, Belgium
Cancer Res 62:5510-6. 2002..These results suggest that HERV-K-MEL is a source of antigens that are targeted by CTLs in melanoma patients and could therefore be used for vaccination... - Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12Shigui Zhu
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
J Immunother 35:680-8. 2012..These results provide support for the use of these TCRs in cancer adoptive immunotherapy trials... - Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCRJoannes F M Jacobs
Department of Pediatric Hemato Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Int J Cancer 120:67-74. 2007..Some rhabdomyosarcomas express several of these genes at high levels. Ewing's sarcomas have an overall low CGG expression... - Cancer immunotherapy with MAGE antigensPierre G Coulie
, , Brussels, Belgium
Suppl Tumori 1:S63-5. 2002 - Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigenPierre Yves Dietrich
Division of Oncology, Laboratory of Tumor Immunology, University Hospital, Geneva, Switzerland
J Immunol 170:5103-9. 2003..1-bearing TCRs, whereas functional outcomes result from the sum of these with other interactions between pMHC complex and TCR... - Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptideDanièle Godelaine
Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium
J Immunol 171:4893-7. 2003..This polyclonality contrasts with the monoclonality of the CTL responses observed in patients vaccinated with MAGE-3.A1 peptide or with an ALVAC recombinant virus coding for this antigenic peptide... - Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cellsNicolas van Baren
Ludwig Institute for Cancer Research, 74 avenue Hippocrate, UCL7459, B 1200 Brussels, Belgium E mail
J Clin Oncol 23:9008-21. 2005.... - [General principles and first clinical trials of therapeutic vaccines against cancer]Jean Francois Baurain
Centre du Cancer, Cliniques Universitaires Saint Luc, Oncology Department, 54 Avenue Hippocrate, B 1200 Bruxelles, Belgique
Bull Cancer 95:327-35. 2008..Current research projects aim at elucidating the mechanisms of this resistance and to develop new vaccination strategies that circumvent this roadblock... - Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathwayFaten El Hage
Institut National de la Sante et de la Recherche Medicale, Unité 753, Laboratoire Immunologie des Tumeurs Humaines, Villejuif, France
Proc Natl Acad Sci U S A 105:10119-24. 2008..This new epitope is, therefore, a promising candidate for cancer immunotherapy... - A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3Martin Hülsmeyer
Institut für Chemie Kristallographie, Freie Universitat Berlin, 14195 Berlin, Germany, Cellectis, 93235 Romainville, France
J Biol Chem 280:2972-80. 2005..The HLA-A1.MAGE-A1.antibody structure is discussed in comparison with those of natural ligands recognizing HLA.peptide complexes... - Monoclonal and recombinant antibodies with T cell receptor-like reactivityAndreas Ziegler
Institut für Immungenetik, Humboldt Universitat zu Berlin, Charite Campus Virchow Klinikum, Germany
Recent Results Cancer Res 176:229-41. 2007.... - Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 moleculesEric M Bluman
Department of Orthopaedic Surgery, Brown University, Providence, Rhode Island, USA
J Orthop Res 25:678-84. 2007..These results suggest that immunotherapy targeted against chondrosarcoma cells is possible... - A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinomaMitsuhiro Takenoyama
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
Int J Cancer 118:1992-7. 2006..These results strengthened the notion that unique tumor-specific antigens are highly represented not only in melanoma but also in other types of tumors, like nonsmall cell lung cancer...